Analysis for Recovery and Loss of Mononuclear Cells and Colony-Forming Units Granulocyte-Macrophage during ex vivo Processing of Autologous Bone Marrow

Vox Sanguinis ◽  
1996 ◽  
Vol 70 (3) ◽  
pp. 132-138
Author(s):  
N. Schwella ◽  
H.G. Heuft ◽  
O. Rick ◽  
R. Blasczyk ◽  
G. Wittmann ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Mononuclear Cells ◽  
Ex Vivo ◽  
Autologous Bone Marrow ◽  
Colony Forming Units ◽  
Autologous Bone

scholarly journals Infusion of freshly isolated autologous bone marrow derived mononuclear cells prevents endotoxin-induced lung injury in an ex-vivo perfused swine model

2013 ◽  
Vol 4 (2) ◽  
pp. 26 ◽  
Author(s):  
Mauricio Rojas ◽  
Richard E Parker ◽  
Natalie Thorn ◽  
Claudia Corredor ◽  
Smita S Iyer ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Lung Injury ◽  
Mononuclear Cells ◽  
Ex Vivo ◽  
Autologous Bone Marrow ◽  
Swine Model ◽  
Autologous Bone

scholarly journals Ex vivo gene therapy in autologous bone marrow stromal stem cells for tissue-engineered maxillofacial bone regeneration

Gene Therapy ◽  
2003 ◽  
Vol 10 (24) ◽  
pp. 2013-2019 ◽  
Author(s):  
S C-N Chang ◽  
H L Chuang ◽  
Y R Chen ◽  
J K Chen ◽  
H-Y Chung ◽  
...  
Keyword(s):  
Stem Cells ◽  
Gene Therapy ◽  
Bone Marrow ◽  
Bone Regeneration ◽  
Ex Vivo ◽  
Autologous Bone Marrow ◽  
Ex Vivo Gene Therapy ◽  
Autologous Bone ◽  
Stromal Stem Cells

scholarly journals Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

Blood ◽  
1992 ◽  
Vol 80 (7) ◽  
pp. 1666-1672
Author(s):  
S Jagannath ◽  
DH Vesole ◽  
L Glenn ◽  
J Crowley ◽  
B Barlogie
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Mononuclear Cells ◽  
Intensive Therapy ◽  
Autologous Bone Marrow ◽  
Blood Stem Cell ◽  
High Dose ◽  
Platelet Recovery ◽  
Gm Csf ◽  
Autologous Bone

To improve the safety of autotransplantation for myeloma, peripheral blood stem cell (PBSC) collection was attempted in 75 previously treated patients after the administration of high-dose cyclophosphamide (HD-CTX; 6 g/m2) with or without granulocyte-macrophage colony- stimulating factor (GM-CSF). Sixty patients subsequently received melphalan 200 mg/m2 (57 patients) or melphalan 140 mg/m2 and total body irradiation (850 cGy) (3 patients) supported by both autologous bone marrow and PBSC; 38 patients received GM-CSF posttransplantation. Among 72 patients undergoing PBSC apheresis, “good” mobilization (greater than 50 colony-forming units granulocyte-macrophage [CFU-GM] per 10(5) mononuclear cells) was achieved when prior chemotherapy did not exceed 1 year and when GM-CSF was used post-HD-CTX; similarly, rapid platelet recovery to 50,000/microL within 2 weeks was associated with “good” PBSC mobilization. These same variables also predicted for rapid engraftment after autotransplantation, so that hematologic recovery (granulocytes greater than 500/microL and platelets greater than 50,000/microL) proceeded within 2 weeks among the 37 patients with “good” PBSC collection. As a result of rapid neutrophil recovery (greater than 500/microL) within a median of 2 weeks, infectious complications both post-HD-CTX and posttransplant were readily manageable, resulting in only one treatment-related death post-HD-CTX. The cumulative response rate (greater than or equal to 75% cytoreduction) for all 75 patients was 68%, with 12-month event-free and overall survival projections of about 85%. Using both bone marrow and PBSC together with GM-CSF, autotransplants are safe and appear effective in myeloma, especially when prior therapy had been limited to less than 1 year. More than 80% of transplanted patients achieved complete hematologic recovery within a median of 1 month posttransplant (granulocytes greater than 1,500/microL; platelets greater than 100,000/microL; hemoglobin greater than 10 g%), thus providing sufficient hematopoietic reserve for further chemotherapy in the event of posttransplant relapse.

scholarly journals Photoradiation models for the clinical ex vivo treatment of autologous bone marrow grafts

Blood ◽  
1987 ◽  
Vol 70 (2) ◽  
pp. 484-489
Author(s):  
J Atzpodien ◽  
SC Gulati ◽  
A Strife ◽  
BD Clarkson
Keyword(s):  
Bone Marrow ◽  
Tumor Cells ◽  
White Light ◽  
Ex Vivo ◽  
Light Exposure ◽  
B Cell Lymphoma ◽  
Autologous Bone Marrow ◽  
Neoplastic Cells ◽  
Drug Concentrations ◽  
Autologous Bone

To assess the potential of photoradiation therapy for the in vitro purging of residual tumor cells from autologous bone marrow (BM) transplants, we studied normal marrow and tumor cell clonogenicity in response to different light-activated compounds by using the fluorescent dyes dihematoporphyrin ether (DHE) and merocyanine-540 (MC- 540). After photoradiation of cells with white light, both DHE and MC- 540 showed high cytocidal activity toward lymphoid and myeloid neoplastic cells but had a significantly lesser effect on normal granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and mixed colony- forming (CFU-GEMM) progenitor cells. Acute promyelocytic leukemia (HL- 60), non-B, non-T, CALLA-positive acute lymphoblastic leukemia (Reh), and diffuse histocytic B cell lymphoma (SK-DHL-2) cell lines were exposed to different drug concentrations in combination with white light at a constant illumination rate of 50,000 lux. With DHE doses varying from 2.0 to 2.5 micrograms/mL and MC-540 concentrations of 15 to 20 micrograms/mL, clonogenic tumor cells could be reduced by more than 4 logs when treated alone or in mixtures with normal irradiated human marrow cells. However, preferential cytotoxicity towards neoplastic cells was highly dependent on the mode of light activation. MC-540 had no substantial effect on malignant lymphoid (SK-DHL-2) and myeloid (HL-60) cells and on normal marrow myeloid (CFU-GM) precursors when drug incubation was performed in the dark and followed by light exposure of washed cells. Equal doses of MC-540 (15 to 20 micrograms/mL) could preferentially eliminate tumor cells under conditions of simultaneous light and drug treatment (30 minutes at 37 degrees C). When using DHE (2.5 micrograms/mL), 29.3%, 46.8%, and 27.5% of normal marrow CFU-GM, BFU-E, and CFU-GEMM, respectively, were spared after sequential drug and light exposure of cells, whereas simultaneous treatment reduced both normal (CFU-GM) and neoplastic cells below the limits of detection. In summary, our results indicate the usefulness of various photoradiation models for the ex vivo treatment of leukemic and lymphomatous bone marrow autografts.

Sign in / Sign up

Export Citation Format

Share Document